Clin Endosc.  2019 Sep;52(5):472-478. 10.5946/ce.2018.152.

Effectiveness of Autologous Platelet-Rich Plasma for the Healing of Ulcers after Endoscopic Submucosal Dissection

Affiliations
  • 1Digestive Disease Center, CHA Bundang Medical Center, CHA University, Seongnam, Korea. cjy6695@dreamwiz.com
  • 2Alanya Alaaddin Keykubat University, School of Medicine Department of Gastroenterology and Hepatology, Antalya, Turkey.

Abstract

BACKGROUND/AIMS
Platelet-rich plasma (PRP) has been used for wound healing in various medical fields. The aim of this study was to evaluate the clinical efficacy and safety of local PRP injections after endoscopic submucosal dissection (ESD).
METHODS
Patients were non-randomly divided into the following two groups: (1) control group in which patients were administered only an intravenous proton pump inhibitor (PPI), and (2) a study group in which patients were administered an intravenous PPI and a topical PRP injection. We assessed the reduction in the ulcer area and stage of the ulcer after the procedure (24 hours, 48 hours, and 28 days after endoscopic surgery).
RESULTS
We enrolled 7 study and 7 control patients. In the study group, the rate of ulcer reduction was 59% compared to 52% in the control group (p=0.372), 28 days after ESD. There were 5 patients in the S stage and 2 patients in the H stage in the study group compared to no patient in the S stage and 7 patients in the H stage in the control group (p=0.05), 28 days after ESD. There were no serious complications in either group.
CONCLUSIONS
The local injection of PRP is a safe and effective procedure for ulcer healing after ESD.

Keyword

Endoscopic submucosal dissection; Platelet-rich plasma; Ulcer healing

MeSH Terms

Humans
Platelet-Rich Plasma*
Proton Pumps
Treatment Outcome
Ulcer*
Wound Healing
Proton Pumps

Figure

  • Fig. 1. Platelet-rich plasma (PRP) preparation.

  • Fig. 2. Method of platelet-rich plasma (PRP) injection. ESD, endoscopic submucosal dissection.

  • Fig. 3. Change of ulcer (endoscopic finding) 24 hours after endoscopic submucosal dissection.(A) Study (platelet-rich plasma) group 24 hours after endoscopic submucosal dissection (ESD). (B) Study (platelet-rich plasma) group 28 days after ESD. (C) Control group 24 hours after ESD. (D) Control group 28 days after ESD.


Cited by  2 articles

The Additive Effect of Platelet-Rich Plasma in the Treatment of Actively Bleeding Peptic Ulcer
Waseem M. Seleem, Amr Shaaban Hanafy
Clin Endosc. 2021;54(6):864-871.    doi: 10.5946/ce.2021.004.

Endless Challenges in Overcoming Complications Associated with Endoscopic Submucosal Dissection
Satoshi Ono, Shun Ito, Kenji Ogata
Clin Endosc. 2019;52(5):395-396.    doi: 10.5946/ce.2019.137.


Reference

1. Kim DS, Jung Y, Rhee HS, et al. Usefulness of the forrest classification to predict artificial ulcer rebleeding during second-look endoscopy after endoscopic submucosal dissection. Clin Endosc. 2016; 49:273–281.
Article
2. Oda I, Nonaka S, Abe S, Suzuki H, Yoshinaga S, Saito Y. Is there a need to shield ulcers after endoscopic submucosal dissection in the gastrointestinal tract? Endosc Int Open. 2015; 3:E152–E153.
Article
3. Ono H, Kondo H, Gotoda T, et al. Endoscopic mucosal resection for treatment of early gastric cancer. Gut. 2001; 48:225–229.
Article
4. Lee SY, Kim JJ, Lee JH, et al. Healing rate of EMR-induced ulcer in relation to the duration of treatment with omeprazole. Gastrointest Endosc. 2004; 60:213–217.
Article
5. Kakushima N, Yahagi N, Fujishiro M, et al. The healing process of gastric artificial ulcers after endoscopic submucosal dissection. Dig Endosc. 2004; 16:327–331.
Article
6. Park JH, Baek EK, Choi CH, et al. Comparison of the efficacy of 4- and 8-week lansoprazole treatment for ESD-induced gastric ulcers: a randomized, prospective, controlled study. Surg Endosc. 2014; 28:235–241.
Article
7. Ye BD, Cheon JH, Choi KD, et al. Omeprazole may be superior to famotidine in the management of iatrogenic ulcer after endoscopic mucosal resection: a prospective randomized controlled trial. Aliment Pharmacol Ther. 2006; 24:837–843.
Article
8. Takao T, Takegawa Y, Shinya N, Tsudomi K, Oka S, Ono H. Tissue shielding with polyglycolic acid sheets and fibrin glue on ulcers induced by endoscopic submucosal dissection in a porcine model. Endosc Int Open. 2015; 3:E146–E151.
Article
9. Takimoto K, Toyonaga T, Matsuyama K. Endoscopic tissue shielding to prevent delayed perforation associated with endoscopic submucosal dissection for duodenal neoplasms. Endoscopy. 2012; 44 Suppl 2 UCTN:E414–E415.
Article
10. Takimoto K, Imai Y, Matsuyama K. Endoscopic tissue shielding method with polyglycolic acid sheets and fibrin glue to prevent delayed perforation after duodenal endoscopic submucosal dissection. Dig Endosc. 2014; 26 Suppl 2:46–49.
Article
11. Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent. 2001; 10:225–228.
Article
12. Molloy T, Wang Y, Murrell G. The roles of growth factors in tendon and ligament healing. Sports Med. 2003; 33:381–394.
Article
13. Akimoto M, Hashimoto H, Maeda A, Shigemoto M, Yamashita K. Roles of angiogenic factors and endothelin-1 in gastric ulcer healing. Clin Sci (Lond). 2002; 103 Suppl 48:450S–454S.
Article
14. Luo JC, Shin VY, Liu ES, et al. Dexamethasone delays ulcer healing by inhibition of angiogenesis in rat stomachs. Eur J Pharmacol. 2004; 485:275–281.
Article
15. Perini R, Wallace JL, Ma L. Roles of platelets and proteinase-activated receptors in gastric ulcer healing. Dig Dis Sci. 2005; 50 Suppl 1:S12–S15.
Article
16. A Hamid MS, Mohamed Ali MR, Yusof A, George J, Lee LP. Platelet-rich plasma injections for the treatment of hamstring injuries: a randomized controlled trial. Am J Sports Med. 2014; 42:2410–2418.
17. Carter MJ, Fylling CP, Parnell LK. Use of platelet rich plasma gel on wound healing: a systematic review and meta-analysis. Eplasty. 2011; 11:e38.
18. Chicharro-Alcántara D, Rubio-Zaragoza M, Damiá-Giménez E, et al. Platelet rich plasma: new insights for cutaneous wound healing management. J Funct Biomater. 2018; 9:E10.
Article
19. Hammond JW, Hinton RY, Curl LA, Muriel JM, Lovering RM. Use of autologous platelet-rich plasma to treat muscle strain injuries. Am J Sports Med. 2009; 37:1135–1142.
Article
20. Kazakos K, Lyras DN, Verettas D, Tilkeridis K, Tryfonidis M. The use of autologous PRP gel as an aid in the management of acute trauma wounds. Injury. 2009; 40:801–805.
Article
21. Lacci KM, Dardik A. Platelet-rich plasma: support for its use in wound healing. Yale J Biol Med. 2010; 83:1–9.
22. Mehrannia M, Vaezi M, Yousefshahi F, Rouhipour N. Platelet rich plasma for treatment of nonhealing diabetic foot ulcers: a case report. Can J Diabetes. 2014; 38:5–8.
Article
23. Picard F, Hersant B, Bosc R, Meningaud JP. Should we use platelet-rich plasma as an adjunct therapy to treat “acute wounds,” “burns,” and “laser therapies”: a review and a proposal of a quality criteria checklist for further studies. Wound Repair Regen. 2015; 23:163–170.
Article
24. Samani MK, Saberi BV, Ali Tabatabaei SM, Moghadam MG. The clinical evaluation of platelet-rich plasma on free gingival graft’s donor site wound healing. Eur J Dent. 2017; 11:447–454.
Article
25. Suthar M, Gupta S, Bukhari S, Ponemone V. Treatment of chronic non-healing ulcers using autologous platelet rich plasma: a case series. J Biomed Sci. 2017; 24:16.
Article
26. Sakita T, Fukutomi H. Endoscopic diagnosis. In : Yoshitoshi Y, editor. Ulcer of stomach and duodenum. Tokyo: Nankodo;1971. p. 198–208.
27. Baniya R, Upadhaya S, Khan J, et al. Carbon dioxide versus air insufflation in gastric endoscopic submucosal dissection: a systematic review and meta-analysis of randomized controlled trials. Clin Endosc. 2017; 50:464–472.
Article
28. Lee HJ, Lee YJ, Lee JY, et al. Characteristics of synchronous and metachronous multiple gastric tumors after endoscopic submucosal dissection of early gastric neoplasm. Clin Endosc. 2018; 51:266–273.
Article
29. Ma L, Elliott SN, Cirino G, Buret A, Ignarro LJ, Wallace JL. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci U S A. 2001; 98:6470–6475.
Article
30. Hwang DL, Lev-Ran A, Yen CF, Sniecinski I. Release of different fractions of epidermal growth factor from human platelets in vitro: preferential release of 140 kDa fraction. Regul Pept. 1992; 37:95–100.
Article
31. O’Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; 88:277–285.
Article
32. Wartiovaara U, Salven P, Mikkola H, et al. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost. 1998; 80:171–175.
Article
33. Yamaguchi N, Anand-Apte B, Lee M, et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J. 1999; 18:4414–4423.
Article
34. Salarinia R, Sadeghnia HR, Alamdari DH, Hoseini SJ, Mafinezhad A, Hosseini M. Platelet rich plasma: effective treatment for repairing of spinal cord injury in rat. Acta Orthop Traumatol Turc. 2017; 51:254–257.
Article
35. Ronci C, Ferraro AS, Lanti A, et al. Platelet-rich plasma as treatment for persistent ocular epithelial defects. Transfus Apher Sci. 2015; 52:300–304.
Article
36. Ghoddusi J, Maghsudlu A, Jafarzadeh H, Jafarian A, Forghani M. Histological evaluation of the effect of platelet-rich plasma on pulp regeneration in nonvital open apex teeth: an animal study. J Contemp Dent Pract. 2017; 18:1045–1050.
37. Tambella AM, Attili AR, Dupré G, et al. Platelet-rich plasma to treat experimentally-induced skin wounds in animals: a systematic review and meta-analysis. PLoS One. 2018; 13:e0191093.
Article
38. Lorenzo-Zúñiga V, Boix J, Moreno de Vega V, Bon I, Marín I, Bartolí R. Efficacy of platelet-rich plasma as a shielding technique after endoscopic mucosal resection in rat and porcine models. Endosc Int Open. 2016; 4:E859–E864.
Article
39. Chahla J, Cinque ME, Piuzzi NS, et al. A call for standardization in platelet-rich plasma preparation protocols and composition reporting: a systematic review of the clinical orthopaedic literature. J Bone Joint Surg Am. 2017; 99:1769–1779.
40. Bernuzzi G, Tardito S, Bussolati O, et al. Platelet gel in the treatment of cutaneous ulcers: the experience of the Immunohaematology and Transfusion Centre of Parma. Blood Transfus. 2010; 8:237–247.
41. Leitner GC, Gruber R, Neumüller J, et al. Platelet content and growth factor release in platelet-rich plasma: a comparison of four different systems. Vox Sang. 2006; 91:135–139.
Article
42. Kim SA, Ryu HW, Lee KS, Cho JW. Application of platelet-rich plasma accelerates the wound healing process in acute and chronic ulcers through rapid migration and upregulation of cyclin A and CDK4 in HaCaT cells. Mol Med Rep. 2013; 7:476–480.
Article
43. Liou E. The development of submucosal injection of platelet rich plasma for accelerating orthodontic tooth movement and preserving pressure side alveolar bone. APOS trends in orthodontics. 2016; 6:5–11.
Article
Full Text Links
  • CE
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr